Competitive Acquisition Vendors Should Pay Drug Returns – CMS Doctor Panel
Competitive acquisition program vendors should be responsible for the cost of wasted or returned products, the Centers for Medicare & Medicaid Services Practicing Physician Advisory Council recommended to the agency
You may also be interested in...
Medicare could award anywhere from five to 250 separate Part B drug vendor contracts under the competitive acquisition program depending on how the Centers for Medicare & Medicaid Services ends up defining bidding areas
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials